Dr Matthew Reynolds Addresses Pre-, Postpandemic Implications for Real-world Data and Research
Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research, as well as implications for future studies.
New Partnerships Bring New Opportunities, Challenges With Data in HEOR
Technological innovation is helping to reinvent the traditional health economics and outcomes research (HEOR) field as traditional and new players partner to leverage data sources.
US Health Plans Addressing Rising Drug Costs With Step Therapy, Value Assessment Frameworks
As the cost of therapies increases, US health plans are utilizing tools like step therapy, to ensure patients try cheaper alternatives first, and value assessment frameworks, to assist with the decision-making process.
Mark Trusheim Speaks on ISPOR Payer Summit, Performance-Based Contracting
Mark Trusheim, MS, BS, strategic director at the NEW Drug Development ParadIGmS program and visiting scientist at Massachusetts Institute of Technology, explains factors involved when considering whether a therapy would be suitable for performance-based contracting.
Gene Therapies Present Reimbursement Challenges That Have Yet to Be Answered
With more than 3000 gene therapies in development, payers will have to grapple with the challenges of paying for these innovative but expensive therapies.
Dr Amy Abernethy: Collaboration Key to Optimize Interpretation of Data in the Evolving HEOR Landscape
Amy Abernethy, MD, PhD, a hematologist/oncologist and palliative medicine physician, and former Principal Deputy Commissioner of the FDA, discusses new collaborations in the health economics and outcomes research (HEOR) landscape.
Using Data to Track COVID-19 Vaccine Uptake and Target Hesitant Communities
During a panel at Virtual ISPOR 2021, speakers presented global perspectives of COVID-19 vaccine rollout and efforts to target vaccine-hesitant communities.
Dr Lou Garrison on HTA Utilization, Opportunities for Growth in the Health Care Marketplace
Lou Garrison, PhD, professor emeritus in the Department of Pharmacy at the University of Washington, explains what is needed to optimize use of health technology assessment (HTA) in the fragmented US health care system.
Dr J. Jaime Caro Discusses Influence of HEOR, Public Health Amid COVID-19
J. Jaime Caro, MDCM, FACP, FRCPC, is chief scientist at Evidera, professor in practice at London School of Economics, and adjunct professor of medicine, epidemiology, and biostatistics at McGill University.
Health Care Use Among Patients With COPD With Pneumonia and the Cost Savings of Switching to Triple Therapy
Two posters presented at Virtual ISPOR 2021 analyzed the health care resource utilization and cost of patients with chronic obstructive pulmonary disease (COPD) with pneumonia, as well as the cost savings of treating patients with frequent or severe COPD exacerbations with a fixed-dose triple therapy.
Building a More Resilient and Sustainable Health System
The COVID-19 pandemic brought together the world and taught health systems how to be resilient and adapt to both predictable and unpredictable changes, said the panelists during the plenary on day 1 of Virtual ISPOR 2021.
Dr Vivian Lee on HEOR Integration Amid COVID-19, Implications for Value-Based Care Transition
Vivian Lee, MD, PhD, MBA, president of health platforms, Verily Life Sciences, discusses examples of health economics and outcomes research (HEOR) use amid the pandemic to optimize patient care, as well as what impact HEOR may have in the transition to a value-based health care system.
Dr Lou Garrison on the Layout of ISPOR 2021, Sessions to Look For
Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington, previews the layout of the virtual 2021 ISPOR annual conference and the myriad of upcoming discussions.
5 Topics of Interest at Virtual ISPOR 2021
The 4-day annual meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research—will cover a wide range of topics. Here are 5 themes to keep an eye out for.
Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings
Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.
Examining the Links Among Diabetes Education, Activity, and Food Insecurity
The presentation at Virtual ISPOR 2020 found that 7% of a group of Medicare beneficiaries with type 2 diabetes was experiencing food insecurity, a rate the lead author found "alarming."
Care Not in Line With Guidelines for HER2-Negative MBC Has Worse Outcomes in Elderly Women
More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.
MS Spending Spiked Over the Past Decade as Costly DMTs Emerged, Reports at ISPOR Show
A new report shows just how much disease modifying therapies (DMTs) have changed the economic landscape of treating multiple sclerosis.
What Innovations Can Improve Detection of Predictors, Severity in Parkinson Disease?
Presented at Virtual ISPOR 2020, researchers examined the efficacy of a machine learning approach in detecting predictors of Parkinson disease (PD), with an additional study testing the use of a statistical model to predict severity of PD.
Discontinuation Rates Matter When Evaluating Biologics in RA, Analysis Finds
Incremental cost-effectiveness ratios (ICERs) must be updated to reflect the fact that some patients discontinue biologics and swap in other products, the authors concluded.
Early Detection Programs May Help Offset Costs of COPD Exacerbations, Studies Find
Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Studies Outline Asthma's Economic Toll
Although the total cost of asthma was more than $80 billion in 2013, the expansion of Medicaid in 2014 aided patients with asthma, according to 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Opioid Use, Economic Burdens of Migraine Detailed in Pair of Studies at ISPOR
At the Virtual ISPOR 2020 conference, researchers presented data on treatment patterns, inpatient and outpatient visits, and pharmacy costs incurred by migraineurs.
What Happens to Patients in the First Year After ILD Diagnosis?
Two studies presented at the Virtual 2020 ISPOR conference examined health care resource utilization and health-related quality of life in interstitial lung disease.
Linking Opportunity Costs and Value Assessments for State and Commercial Payers
When deciding which treatments to cover, states and commercial payers must wrestle with opportunity costs as new therapeutics come to market. A panel at Virtual ISPOR 2020 discussed some of the factors that go into those decisions.
Impact of OFF Periods in Caregivers of Patients With Parkinson Disease, Preferred On-Demand Treatments
In 2 abstracts presented at the Virtual ISPOR 2020 meeting, researchers discuss how “OFF” episodes among patients with Parkinson disease may contribute to an increased degree of burden for respective caregivers, with patient preferred on-demand treatments for these episodes also detailed.
How Will the Pandemic Shape Health Care Policy of the Future?
At the opening session of this year's Virtual ISPOR 2020 conference, panelists shared their views on what future health care systems can learn from the current pandemic crisis.
Virtual ISPOR Panel to Examine Next Steps in Value Assessment
Two of the panelists appearing during the Virtual ISPOR 2020 meeting preview what's needed in improving value assessment: Lou Garrison, PhD, of the University of Washington, and Leah Howard, JD, of the National Psoriasis Foundation.
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
2 Clarke Drive Cranbury, NJ 08512